<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04648761</url>
  </required_header>
  <id_info>
    <org_study_id>OPTIMAL</org_study_id>
    <nct_id>NCT04648761</nct_id>
  </id_info>
  <brief_title>Individualized Titration of Biologics in Severe Asthma</brief_title>
  <acronym>OPTIMAL</acronym>
  <official_title>OPTIMAL - Individualized Titration of Biologics in Severe Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bispebjerg Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      OPTIMAL is a non-inferiority, open label randomized clinical trial thats investigates a&#xD;
      titration algorithm for anti IL 5 biologics in severe asthma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>One group will have their biological treatment titrated via the OPTIMAL algorithm and a control group will continue their biological treatment unchanged.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of proportions of patients with exacerbations aften one year in each group</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients on reduced dose of biologics at the end of trial</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>OPTIMAL group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will have their anti IL 5 biologics titrated by OPTIMAL algorithm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group will continue their treatment with anti IL 5 biologics unchanged</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OPTIMAL algorithm</intervention_name>
    <description>The OPTIMAL algorithm titrates anti IL 5 treatment by addjusting the intervals between injections by FEV1, blood eosinophils and exacerbations.</description>
    <arm_group_label>OPTIMAL group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed written consent&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Correct asthma diagnosis as judged by (sub)-investigator&#xD;
&#xD;
          -  Treatment with anti-IL5/IL5r for 12 months or longer&#xD;
&#xD;
          -  Treatment with the same biologic drug in the last 12 months&#xD;
&#xD;
          -  No exacerbations requiring OCS in the last 12 months&#xD;
&#xD;
          -  Blood eosinophils &lt; 0.30 in the last 12 months&#xD;
&#xD;
          -  No daily OCS for more than 3 days in the last 12 months with asthma as indication&#xD;
&#xD;
          -  Correct inhalation technique for using regular inhalers&#xD;
&#xD;
          -  Acceptable adherence to ICS (according to FMK as judged by (sub)-investigator)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Pregnant or breastfeeding females&#xD;
&#xD;
          -  Lack of effective contraception in women of childbearing potential who are sexually&#xD;
             active with a non-sterilized male partner. Women of childbearing potential are defined&#xD;
             as those who are not surgically sterile (e.g. bilateral tubal ligation, bilateral&#xD;
             oophorectomy, complete hysterectomy) or postmenopausal (defined as 12 months with no&#xD;
             menses without an alternative medical cause). Effective contraception is defined as&#xD;
             intrauterine device (hormonal or non-hormonal), sexual abstinence, bilateral tubal&#xD;
             occlusion, combined (estrogen and progesterone) hormonal contraception (oral,&#xD;
             intravaginal and transdermal) and progesterone-only hormonal contraception (oral,&#xD;
             injectable and implantable).&#xD;
&#xD;
          -  Previous medical history or evidence of an uncontrolled intercurrent illness such as&#xD;
             but not limited to (e.g. Autoimmune disease, immunodeficiency, immunosuppression,&#xD;
             malignant neoplastic conditions with current relevance) that in the opinion of the&#xD;
             investigator may compromise the safety of the subject in the study or interfere with&#xD;
             evaluation of the algorithm or reduce the subject's ability to participate in the&#xD;
             study. Subjects with well-controlled comorbid disease (eg, hypertension,&#xD;
             hyperlipidaemia, gastroesophageal reflux disease) on a stable treatment regimen for 15&#xD;
             days prior to inclusion are eligible.&#xD;
&#xD;
          -  Any concomitant respiratory disease that in the opinion of the investigator and/or&#xD;
             medical monitor will interfere with the evaluation of the algorithm or interpretation&#xD;
             of subject safety or study results (eg. chronic obstructive pulmonary disease, cystic&#xD;
             fibrosis, pulmonary fibrosis, bronchiectasis, allergic bronchopulmonary aspergillosis,&#xD;
             eosinophilic granulomatosis polyangitiis, alpha-1-antitrypsin deficiency, Wegeners&#xD;
             granulomatosis, Sarcoidosis).&#xD;
&#xD;
          -  Any clinically relevant abnormal findings in haematology or clinical chemistry&#xD;
             (laboratory results from Visit 0), physical examination, vital signs during the&#xD;
             screening, which in the opinion of the investigator, may put the subject at risk&#xD;
             because of his/her participation in the study, or may influence the results of the&#xD;
             study, or the subject's ability to participate in the study.&#xD;
&#xD;
          -  Unwillingness or inability to follow the procedures outlined in the protocol.&#xD;
&#xD;
          -  History of chronic alcohol- or drug abuse 12 months prior to inclusion&#xD;
&#xD;
          -  Concurrent enrolment in another clinical study involving an investigational treatment.&#xD;
&#xD;
          -  Use of immunosuppressive medication (eg, methotrexate, troleandomycin, oral gold,&#xD;
             cyclosporine, azathioprine, intramuscular long-acting depot corticosteroids or any&#xD;
             experimental anti-inflammatory therapy) within 3 months prior to inclusion and during&#xD;
             the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Respiratory Research Unit, Med. Clinic I, Bispebjerg Hospital, Bispebjerg Bakke 23</name>
      <address>
        <city>Copenhagen</city>
        <state>NV</state>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>December 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bispebjerg Hospital</investigator_affiliation>
    <investigator_full_name>Celeste Porsbjerg</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

